Validation of a surveillance-based definition for hepatitis B treatment eligibility.


Approximately 100,000 New York City (NYC) residents are currently diagnosed with chronic hepatitis B virus (HBV) infection.1 Routine monitoring and treatment, where indicated, are necessary to reduce HBV disease progression. Using the 2017 European Association for the Study of the Liver (EASL) 2 guidelines on HBV infection management, we developed a surveillance-based definition for treatment eligibility. Validation of this definition will support the creation of a population-level HBV care continuum, which will allow us to monitor gaps from HBV diagnosis to viral suppression and to develop public health interventions to address these gaps.

Objective: To assess the accuracy of a surveillance-based definition for hepatitis B treatment eligibility among New York City residents with chronic hepatitis B infection.

Original Publication Year: 
Event/Publication Date: 
January, 2019

June 18, 2019

Contact Us

NSSP Community of Practice



This website is supported by Cooperative Agreement # 6NU38OT000297-02-01 Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nation's Health between the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of CDC. CDC is not responsible for Section 508 compliance (accessibility) on private websites.

Site created by Fusani Applications